Login / Signup

Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.

Michael M TunneyPeter A B Wark
Published in: The European respiratory journal (2023)
Keyphrases
  • cystic fibrosis
  • pseudomonas aeruginosa
  • lung function
  • oxidative stress
  • stem cells
  • air pollution
  • mesenchymal stem cells
  • cell therapy